Down 17%, does the GSK share price scream buy?

It has been far from a smooth journey for the GSK share price recently. But this Fool likes the look of the stock now that it is down nearly 20%.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a turbulent 12 months for the GSK (LSE: GSK) share price. Back then it was trading for 1,316.6p. Today, it’s 1,509.9p, or 14.7% higher.

But that doesn’t paint the full picture. During that time, the stock has been on a roller-coaster ride. And shareholders have certainly had to brace themselves at points.

Right now, the stock is down around 17% from its 52-week high after a recent tumble. I’m sensing a buying opportunity.

Should you invest £1,000 in Diageo right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo made the list?

See the 6 stocks

An uncertain period

Before I explain why, it’s best to explore what’s been behind the volatility that its share price has been experiencing. There’s one main factor.

It’s down to potential litigation related to Zantac, a heartburn drug that was removed from the market in 2019 after being linked to cancer. While this has been ongoing for a few years, there have been a couple of developments this year.

The most recent update was the catalyst for its share price decline. A Delaware judge ruled in favour of more than 70,000 lawsuits related to the drug and its link to causing cancer going forward. Its share price slid around 11% on the back of the news.

It hasn’t got much better from there. Since then, the stock has continued on its spiral. It has lost a further 5.5% of its value despite GSK saying it will appeal and “vigorously defend itself” against the claims.

Valuation

Yet despite the uncertainty this creates, I think GSK looks like a bargain. Let’s start with its attractive valuation.

It currently trades on a price-to-earnings (P/E) ratio of 13.8 and a forward P/E of 10.3. I think that looks like good value. Its long-term historical average is closer to 15, suggesting there may be growing room in today’s share price.

What’s more, that’s below the global sector average. It’s significantly cheaper than its rival AstraZeneca, which is currently trading on a P/E ratio of 37.8.

Income

Its falling share price also translates to a meatier dividend yield. It pays out 3.9%, above the FTSE 100 average (3.6%). Last year its dividend payment rose 5.5% to 58p. The business has given 2024 guidance of a 60p dividend, a 3.4% rise.

Alongside its yield, I also like the stability it can provide over the long term as it’s a defensive stock. That may sound contradictory given its recent volatility. But with it providing essential needs, such as vaccines and medicines, this means it’ll always be in demand regardless of external factors such as economic uncertainty. We saw this last year when its revenue and earnings grew 3.4% and 11%, respectively.

I’d buy

I’m fully aware of the risk with Zantac, which is large. So much so that broker UBS recently downgraded its rating for the stock from ‘buy’ to ‘neutral’. These sorts of legal complications are a major risk when investing in pharmaceutical stocks.

But even so, despite downgrading the stock, UBS alluded to GSK having an attractive valuation, and that’s what’s drawing me in. On top of that, the major bank Citi put a ‘buy’ rating on the stock earlier this month.

I think now could be a smart time for investors to consider cheap GSK shares. If I had the cash, I’d happily buy the stock today.

Should you invest £1,000 in Diageo right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »